CorMedix Inc. (NASDAQ: CRMD) saw its stock price surge 5.20% in pre-market trading on Tuesday following the release of its first-quarter 2025 financial results, which significantly exceeded analyst expectations.

The biopharmaceutical company reported earnings per share (EPS) of $0.30, surpassing the consensus estimate of $0.24 by 25%. This marks a substantial improvement from the $0.25 loss per share reported in the same quarter last year. CorMedix's revenue also impressed, coming in at $39.08 million, beating analyst projections of $36 million by 8.55%.

Investors were further encouraged by CorMedix's strong cash position, with the company reporting cash and investments of $77.5 million at the end of the quarter. Additionally, CorMedix provided an optimistic outlook, stating that it expects to reach the high end of its first-half sales guidance range of $62 million to $70 million. This positive financial performance and forward-looking statement likely contributed to the stock's pre-market rally, as investors anticipate continued growth and improved profitability for the company.